FDA Accepts BioMarin's sNDA for Full VOXZOGO Approval in Achondroplasia — BioMarin Pharmaceutical Inc.

Event summary

FDA accepted BioMarin's sNDA for full approval of VOXZOGO in achondroplasia, setting a PDUFA target date of February 28, 2027.
Submission supported by long-term data from three ongoing studies (111-205, 111-208, and 111-302) showing improvements in growth and skeletal health outcomes.
VOXZOGO would be the first therapy for achondroplasia to convert from accelerated approval to traditional approval if approved.
Current accelerated approval was granted in 2021 based on annualized growth velocity.

The big picture

BioMarin's sNDA submission for VOXZOGO marks a critical step in converting its accelerated approval to full approval, leveraging extensive long-term clinical data. This move aligns with broader industry trends toward more comprehensive evidence requirements for rare disease therapies, particularly those targeting skeletal growth disorders. The outcome will influence BioMarin's strategic positioning in the achondroplasia treatment landscape and could set a precedent for similar therapies.

What we're watching

Regulatory Outcome: Whether the FDA will grant full approval by the PDUFA target date of February 28, 2027.
Clinical Impact: How long-term data on adult height and skeletal health outcomes will influence VOXZOGO's market position.
Market Expansion: The pace at which BioMarin can expand VOXZOGO's reach beyond the U.S. into other global markets.